-
.
- Tonix Pharmaceuticals Holding Corp TNXP will certainly reapportion sources and also money to enhance its pipe and also concentrate on its mid and also late-stage medical programs within its core main nerves (CNS) profile.
- .(* )The business is ceasing the registration of brand-new individuals in the Stage 2 test in fibromyalgia-type Lengthy COVID. The about 60 individuals enlisted will certainly be complied with to conclusion, with topline information anticipated in Q3 of 2023.
- Additionally See:
- Tonix Pharmaceuticals Seeks To Reinforce Its COVID-19 Pipe With This New Procurement
. 2023 Drivers:
.
- Acting evaluation outcomes of Stage 3 durable research study of TNX-102 SL (sublingual cyclobenzaprine tablet computers) for fibromyalgia are anticipated in Q2 of 2023, and also topline outcomes are anticipated in Q4 of 2023.
-
.
- Acting evaluation outcomes of Stage 2 avoidance research study of TNX-1900 (intranasal potentiated oxytocin) for persistent migraine headache prepared for in Q4 2023.
- Acting evaluation outcomes of Stage 2 UPLIFT research study of TNX-601 EMERGENCY ROOM (tianeptine hemioxalate extended-release tablet computers) for significant depressive problem in the 4th quarter of 2023.
- .
.
.
.(* )Money and also money matchings of about $120.2 million since Dec. 31, 2022.
.
- TNXP shares are down 1.56% at $0.57 on the last check Tuesday.
- © 2023 Benzinga.com. Benzinga does not give financial investment suggestions. All civil liberties scheduled.
.(* )The pipe adjustment lowers financial investment in a number of longer-term programs, especially COVID-19-related research studies, and also hold-ups the begin of a posttraumatic tension problem (PTSD) research study in Kenya.
.
.
Rate Activity:
.
